0001104659-24-044861.txt : 20240408
0001104659-24-044861.hdr.sgml : 20240408
20240408193227
ACCESSION NUMBER: 0001104659-24-044861
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240408
DATE AS OF CHANGE: 20240408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mehta Vimal
CENTRAL INDEX KEY: 0001733369
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38410
FILM NUMBER: 24830834
MAIL ADDRESS:
STREET 1: 780 EAST MAIN STREET
STREET 2: C/O BIOXCEL THERAPEUTICS, INC.
CITY: BRANFORD
STATE: CT
ZIP: 06405
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001720893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 821386754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-643-8060
MAIL ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
tm2411220-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-14
0
0001720893
BioXcel Therapeutics, Inc.
BTAI
0001733369
Mehta Vimal
C/O BIOXCEL THERAPEUTICS, INC.
555 LONG WHARF DRIVE, 12TH FLOOR
NEW HAVEN
CT
06511
1
1
0
0
CEO and President
1
Common Stock
2024-03-14
4
M
0
2610
A
34832
D
Common Stock
2024-03-15
4
M
0
14000
A
48832
D
Common Stock
2024-04-04
4
S
0
829
2.62
D
48003
D
Common Stock
2024-04-04
4
S
0
4439
2.6247
D
43564
D
Common Stock
2000
I
By spouse
Common Stock
8546750
I
By BioXcel LLC
Restricted Stock Units
2024-03-14
4
M
0
2610
0.00
D
Common Stock
2610
20875
D
Restricted Stock Units
2024-03-15
4
M
0
14000
0.00
D
Common Stock
14000
42000
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $2.62 to $2.65. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote.
These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
/s/ Richard Steinhart, as Attorney in Fact for Vimal Mehta, Ph.D.
2024-04-08